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Intermittent Erlotinib in Combination with Pemetrexed
Phase I Schedules Designed to Achieve Pharmacodynamic Separation
Angela M. Davies, MD,* Cheryl Ho, MD,† Laurel Beckett, PhD,* Derick Lau, MD, PhD,*
Sidney A. Scudder, MD,* Primo N. Lara, MD,* Natasha Perkins, BS,* and David R. Gandara, MD*
Introduction: Epidermal growth factor receptor tyrosine kinase
inhibitors given concurrently with chemotherapy do not improve
patient outcomes compared with chemotherapy alone in advanced
non-small cell lung cancer (NSCLC). Pharmacodynamic separation
by intermittent delivery of epidermal growth factor receptor tyrosine
kinase inhibitors with chemotherapy may increase efficacy by over-
coming hypothesized antagonism.
Methods: Two dose-escalating phase I trials (arm A and arm B)
were conducted simultaneously. Pemetrexed was given every 21
days (500 mg/m2 intravenously). In arm A, erlotinib was given
weekly on days 2, 9, and 16 (800–1400 mg). In arm B, erlotinib was
given on days 2 to 16 (150–250 mg). Patients continued therapy
until disease progression or unacceptable toxicity.
Results: Forty-two patients with advanced solid tumors, including
16 NSCLC, were treated. Patient characteristics included median
age of 63 (range, 29–77), 19 males, and Karnofsky performance
status 90/90  27/15. The median number of cycles was 2.
Treatment was well tolerated. Planned dose escalation was com-
pleted without reaching a maximum tolerated dose. Dose-limiting
toxicities included grade 3 infection/fever (arm A: 500/1200) and
grade 3 infection/neutropenia (arm B: 500/150). Rash frequency was
55% in arm A and 90% in arm B. There were six partial responses (four
lung, one head and neck, one breast) and 16 stable diseases. Four
patients with NSCLC remained on therapy for 9, 16, 16, and 22 cycles.
Conclusions: We report the first clinical trial to test intermittent
erlotinib plus pemetrexed. Pemetrexed 500 mg/m2 and weekly
erlotinib 1400 mg (arm A) or pemetrexed 500 mg/m2 and erlotinib
250 mg on days 2 to 16 (arm B) are feasible and well tolerated. Arm
B efficacy is being examined in a randomized phase II trial for
second-line NSCLC.
Key Words: Erlotinib, Pemetrexed, Pharmacodynamic separation,
Non-small cell lung cancer, Intermittent dosing.
(J Thorac Oncol. 2009;4: 862–868)
Epidermal growth factor receptor (EGFR)-targeted therapyhas established itself as an important treatment option in
advanced non-small cell lung cancer (NSCLC). Erlotinib
(Tarceva, OSI-774, OSI Pharmaceuticals, Inc., Boulder, CO)
is an oral, reversible tyrosine kinase inhibitor that blocks the
EGFR pathway, inhibiting proliferation, differentiation, and
angiogenesis. It is indicated as a single agent for advanced
NSCLC in the second-line setting and in combination with
gemcitabine for advanced pancreatic cancer.1,2 Erlotinib has a
favorable side effect profile, with the predominant toxicities
being rash and diarrhea, which are both amenable to support-
ive measures.
Pemetrexed (Alimta, LY231514, Eli Lilly and Company,
Indianapolis, IN) is a multitargeted antifolate that inhibits three
enzymes involved in folate metabolism (thymidylate synthase,
dihydrofolate reductase, and glycinamide ribonucleotide
formyltransferase) and purine and pyrimidine synthesis. This
agent has a broad spectrum of activity in multiple tumor
types. Indications for single-agent pemetrexed include treat-
ment of second-line advanced NSCLC and, in combination
with cisplatin, treatment of mesothelioma.3,4 Pemetrexed is
well tolerated, and administration with B12 and folate sup-
plementation reduces the significant toxicities associated with
this drug (myelosuppression and mucositis).
Despite its clinical efficacy as a single agent and pre-
clinical data suggesting additive to synergistic effects, the
addition of the EGFR tyrosine kinase inhibitors (TKIs) (ge-
fitinib or erlotinib) to frontline platinum-based chemotherapy
proved no more effective than chemotherapy alone in four
large randomized trials in an unselected patient population.5–8
Although selection of patients based on EGFR status or EGFR
mutations may help predict likelihood of benefit from EGFR-
TKI therapy, a phase III second-line NSCLC study of erlotinib
demonstrated that virtually all categories of patients experienced
improved survival, such that patient selection alone does not
account for the absence of benefit observed with EGFR-TKI
plus chemotherapy.1
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Potential antagonism is another possible explanation
for the lack of additive effects between EGFR-TKIs and
chemotherapy. In vitro data by Tracey et al.9 showing that
EGFR-TKIs result in growth arrest (cytostatic effect) in
NSCLC lines characterized as EGFR wild type suggest that
when EGFR-TKIs are administered concurrently with che-
motherapy the G0/G1 cell cycle arrest of the EGFR-TKIs
may interfere with the cell cycle-specific (S and G2/M phase)
cytotoxicity of chemotherapy. Multiple preclinical studies
support sequence specificity and a schedule-dependent inter-
action, such that the greatest levels of apoptosis are seen with
chemotherapy followed by erlotinib.10–13 Therefore, we hy-
pothesized that sequential administration of an EGFR-TKI
with chemotherapy may be superior to concurrent adminis-
tration. Previous clinical studies with the combination of
docetaxel and intermittent erlotinib have shown striking ef-
ficacy with the intermittent dosing strategy, although it was
accompanied by an increase in toxicity.14,15
This study was designed to assess the safety and toler-
ability of two different schedules of intermittent erlotinib in
combination with pemetrexed and allow for the selection of




Patients with histologically or cytologically confirmed
advanced solid tumors were eligible. Other eligibility criteria
included age 18 years, life expectancy of more than 12
weeks, and a performance status of 0 to 2. Patients may have
had any number of prior chemotherapy regimens, prior che-
motherapy or radiotherapy must have been completed at least
4 or 2 weeks, respectively, before study entry, and all signif-
icant previous treatment-related toxicities had to be resolved.
Adequate hematologic (absolute neutrophil count1500/L,
platelet count 100,000/L), renal (serum creatinine 1.5
mg/dL or a calculated creatinine clearance45 mL/min), and
hepatic function (serum bilirubin 1.5 times the institutional
upper limit of normal and aspartate aminotransferase within
2.5 times the upper limit of normal) were required. Patients
with asymptomatic, treated brain metastasis (surgical resec-
tion or radiotherapy) were eligible if they were neurologically
stable and off steroids for at least 4 weeks. Patients who had
previously received EGFR-targeted therapy or pemetrexed
were excluded. Patients could not take nonsteroidal anti-
inflammatory agents or salicylates 2 days before or 2 days
after (5 days before or after for long-acting nonsteroidal
anti-inflammatory agents) administration of pemetrexed be-
cause of concerns of increased risk of renal toxicity. Patients
with clinically significant ophthalmologic abnormalities or
other disorders that might increase the risk of corneal epithe-
lial injury were excluded. Patients who were pregnant or had
unstable medical conditions were also excluded. Patients of
childbearing potential were required to use a medically accept-
able contraceptive. The Institutional Review Board at the Uni-
versity of California Davis Campus approved the protocol, and
all patients provided written informed consent to participate.
Dose-Limiting Toxicity and Maximum
Tolerated Dose Definitions
A dose-limiting toxicity (DLT) was defined as any of
the following that occurred within the first cycle of treatment:
any grade 4 thrombocytopenia (10,000/mm3) or grade 3
(10,000–50,000/mm3) thrombocytopenia associated with
bleeding, requirement for transfusion, or lasting greater than
7 days; and febrile neutropenia or neutropenia (absolute
neutrophil count 1.0  109) with documented infection.
Nonhematologic DLT was defined as any other  grade 3
nonhematologic toxicity that was clinically significant and
considered by the investigator to be related to study drug,
with the exception of alopecia. In a subsequent amendment to
the study, grade 3 rash based solely on pain was not consid-
ered a DLT. Toxicity was graded according to the National
Cancer Institute Common Toxicity Criteria Adverse Events
version 3.0.
All patients treated at a given dose level were observed
for a minimum of 21 days after the start of the first course
(i.e., treatment cycle 1) before accrual to the next dose level
was allowed. There was no intrapatient dose escalation.
Patients were accrued in cohorts of three patients per dose
level. If none in three patients experienced a DLT, three
patients were treated at the next dose level. If DLT attribut-
able to the treatment was experienced in one of three patients,
three more patients (for a total of six) were treated at that dose
level. If no additional DLT was observed at the expanded
dose level (i.e., one of six with DLT), the dose was escalated.
Escalation was to be terminated when two or more patients
experienced any DLT attributable to study drugs at a given dose
level. Patients were considered assessable for DLT if they
completed at least one cycle of therapy or experienced a DLT.
The maximum tolerated dose (MTD) was defined as the
highest dose level at which no more than one patient expe-
rienced a DLT when at least six patients were treated at that
dose and were assessable for toxicity or when the final dose
level was reached.
Treatment Plan
Patients were treated on one of the two independently
accrued treatment arms after the predetermined dose escala-
tion scheme (Table 1). Patients were accrued in cohorts of
three patients to each dose level. Because only one arm of the
TABLE 1. Dose Levels










3 800 500 3 150 500
3 1000 500 3 200 500
6 1200 500 6 250 500
6 1400 500
4 Unassessable for DLTb 2 Unassessable for DLTc
a Six patients treated in initial cohort not included here but described in the text.
b One at 800 mg, two at 1200 mg, and one at 1400 mg.
c One at 200 mg and one at 250 mg.
PO, oral; IV, intravenous; DLT, dose-limiting toxicity.
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trial was open for accrual at a time, treatment arm A was the
first arm to begin accrual. Once accrual to the first dose level
on treatment arm A was completed, treatment arm B was
opened for accrual to its first dose level. Accrual was con-
tinued in this alternating fashion between both arms. This was
intended to be a study of two separate phase I trials run
concurrently to obtain simultaneous toxicity data of two differ-
ent schedules of these agents, and not as a comparative study.
In arm A, pemetrexed was administered intravenously
on day 1 of a 21-day cycle and oral erlotinib was given
weekly on days 2, 9, and 16. In arm B, pemetrexed was
delivered intravenously on day 1 of a 21-day cycle and oral
erlotinib was given on days 2 to 16. To ameliorate symptoms
known to be associated with pemetrexed treatment, all pa-
tients received dexamethasone 4 mg orally twice daily for 3
days starting the day before pemetrexed, vitamin B12 1000 g
intramuscularly 1 week before starting treatment and every 9
weeks during treatment, and folic acid 350 g orally daily
starting 5 to 7 days before treatment. Erlotinib was taken
orally in the morning with 200 ml of water 1 hour before or
2 hours after meals. Treatment with both drugs was continued
in the absence of disease progression, provided patients were
clinically benefiting and tolerating treatment. After six cycles
of pemetrexed and intermittent erlotinib, patients were per-
mitted to continue the erlotinib monotherapy (Figure 1).
Patient Assessments
Before each cycle, the patients’ medical history was
reviewed and a physical examination was done. Weekly
complete blood counts, including white blood cell differen-
tial, were performed. Serum chemistry, including electro-
lytes, calcium, magnesium, glucose, and creatinine, and liver
function tests were performed every 3 weeks. Adverse events
were assessed before each cycle using the National Cancer
Institute Common Toxicity Criteria Adverse Events version
3.0. Response to therapy was evaluated every two cycles with
computed tomographic scans using RECIST criteria. Trough
plasma concentrations of erlotinib and its metabolite, OSI-
420, were determined using a validated liquid chromatog-
raphy-mass spectroscopy/mass spectroscopy assay at the
end of cycle 1 for both weekly and daily erlotinib dose
cohorts.16 Tumor tissue was not collected in the phase I
component of this trial.
Efficacy Evaluation
Although not a primary outcome of this phase I study,
efficacy of these regimens was evaluated every two cycles
with computed tomographic scans. Patients with assessable
or measurable tumor who completed two cycles of therapy
were included in the analysis of tumor response.
RESULTS
Of the 42 patients enrolled, 36 were assessable for
DLT. The median age was 63 years (range, 28–77) and most
had good performance status. There were 19 male and 23
female participants in the study. The most common tumor
type was NSCLC (38%) followed by ovarian carcinoma
(17%). Patients had received a median of three prior therapies
(Tables 2, 3).
Dose-Limiting Toxicity
Twenty-two patients were accrued to arm A. Four
patients were not assessable for DLT: one patient took erlo-
tinib on wrong days, two patients took the wrong dose of
erlotinib, and one patient had erlotinib held because of hos-
pitalization for chronic obstructive pulmonary disease. In arm
A (pemetrexed with weekly erlotinib), no DLTs were ob-
served at dose level 1 or 2 with three patients enrolled in each.
Because one patient at dose level 3 developed a DLT (grade
3 infection with fever), three additional patients were treated
with no subsequent DLTs. Six patients were subsequently
treated on dose level 4 (erlotinib 1400 mg and pemetrexed
500 mg/m2) with no DLTs, so the planned dose escalation
was completed without reaching an MTD in arm A.
Twenty patients were accrued to arm B, two of whom
were not assessable for DLT because they took the wrong
dose of erlotinib. In arm B (pemetrexed with daily erlotinib),
patients were enrolled in two separate cohorts. In an initial
cohort of six patients at two different dose levels, significant
toxicity was seen and halted further accrual until review by
the local Data Safety and Monitoring Board (DSMB). After
review by the DSMB, a second cohort of patients was
accrued to the same dose levels in arm B without significant
toxicity. Specifically, in the initial cohort of patients, two
patients were enrolled on dose level 1 (erlotinib 150 mg and
pemetrexed 500 mg/m2) without a DLT, but a third patient
developed a rash determined to be grade 3 on the basis of pain
around the nasolabial folds. When a fourth patient enrolled at
the same dose level developed grade 3 infection without
neutropenia (two of four patients with DLT), there was
de-escalation to dose level 1 (erlotinib 100 mg and pem-
etrexed 500 mg/m2). On this dose level, one of the two
patients treated developed grade 3 epistaxis with grade 3
Arm A Day 1 Day 2 Day 9 Day 16 Day 22 
Erlotinib  X X X  





Arm B Day 1 Days 2 – 16   Day 22 
Erlotinib  X    







FIGURE 1. Patients were treated on one of two independently accrued treatment arms after the predetermined dose escala-
tion scheme. Arm A: IV pemetrexed on day 1 of a 21-day cycle  weekly erlotinib on days 2, 9, and 16. Arm B: IV pem-
etrexed on day 1 of a 21-day cycle  oral erlotinib on days 2–16. IV, intravenous.
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thrombocytopenia (this patient had a metastatic germ-cell
tumor with prior bone marrow transplant on concomitant low
molecular weight heparin for deep vein thrombosis). This
resulted in closure of arm B because of unexpected toxicity.
The principal investigator requested review of the un-
expected toxicity by the cancer center DSMB. The DSMB
reviewed all patients accrued to this study and concluded that
the grade 3 epistaxis could be attributed to other patient factors
at the time of the adverse event (treatment with low molecular
weight heparin and prior bone marrow transplant). In addition,
given that rash was a known side effect of both erlotinib and
pemetrexed and that the experience of grade 3 rash did not
compromise the safety of the patient in the study, the DSMB
recommended amending the protocol such that a grade 3 rash
based solely on pain would not be considered a DLT.
As a result of these determinations, the DSMB recom-
mended and the institutional review board allowed arm B to
be reopened and dose escalation to be restarted from dose
level 1. Subsequently, in this second cohort, three patients
each were enrolled at dose levels 1 and 2 with no DLT, and
there was no DLT observed in six patients enrolled in dose
level 3 (erlotinib 250 mg and pemetrexed 500 mg/m2). As
with arm A, dose escalation was completed without reaching
an MTD.
Toxicities
The most common treatment-related nonhematologic
adverse event was rash (55% arm A, 90% arm B; Table 4).
Although treatment-related hematologic adverse events were
common in both arms (including leucopenia, neutropenia,
and reduced hemoglobin), there were limited clinically sig-
nificant grade 3 or 4 hematologic or nonhematologic toxici-
ties (Tables 4, 5). One patient with primary hepatocellular
carcinoma died of liver failure 4 days after initiation of study
treatment. The erlotinib pill count at the time of hospitaliza-
tion suggested that the patient had taken six extra tablets.
Thus, given the patient did not follow protocol therapy
instructions, he/she was considered not assessable for DLT.
Antitumor Activity
Among the 16 patients in arm A assessable for re-
sponse, 5 patients with NSCLC had a partial response, with
durations ranging from 3 to 16 months (Table 6). Five
patients had stable disease: two parotid malignancies (dura-
tion 5–16 months from date of enrollment), one NSCLC (12
months), one pancreatic cancer (2 months), and one prostate
cancer (2 months). Disease progression occurred in eight
patients; 2 of these patients discontinued treatment because of
the investigator’s choice—one with the comment “disease
progression” and the other with the comment “worsening
performance status.” The protocol definition for assessable
disease was completion of two cycles of protocol therapy.
Four patients received a single-cycle therapy, and thus per
protocol were not considered assessable for response; two chose
to discontinue study participation prior to evaluation—one due
to concern about increased prostate-specific antigen and one
following a decision to go on hospice.
Among the 16 patients assessable for response in arm
B, one patient with breast cancer had a partial response for 4
months before choosing to stop treatment because of rash.
There were 10 patients with stable disease: 4, ovarian carci-
noma; 2, prostate cancer; 2, NSCLC; 1, head and neck; and 1,
sarcoma. The duration of stable disease ranged from 2 to 8
months (median 5 months). Five patients in arm B had
progressive disease. Among the four patients considered not
assessable for response, three patients chose to discontinue
study participation because of intolerable side effects (two
specifically because of rash) and one patient was withdrawn
by the treating physician because of prolonged hospitalization
for gastric outlet obstruction associated with metastatic ovar-
ian cancer.
Pharmacokinetic Analyses
Trough pyruvate kinase plasma samples were obtained
from 10 patients in three different dose levels (150 mg/d, 800
mg/wk, and 1000 mg/wk) at the end of cycle 1 (day 21) and
sent to OSI Pharmaceuticals for evaluation. The lower limit
of quantitation was 1.00 ng/ml for each analyte (below limit
of quantitation [BLQ] 1.00 ng/ml). The median (range)
trough plasma concentrations of erlotinib were 5.06 (BLQ–
12.2), 96.7 (82.4–173), and 807 (168–884) ng/ml, for the
TABLE 2. Baseline Patient Characteristics
Patients enrolled 42
Sex (male/female) 19/23
Median age (yr) 63 (28–77)
KPS (80/80) 7 vs. 35





Head and neck 5
Breast 3
Other 7a
a Esophageal, testes, central nervous system, sarcoma, vaginal, pancreas, and liver.
KPS, Karnofsky performance status; NSCLC, non-small cell lung cancer.
TABLE 3. Baseline NSCLC Patient Characteristics
Patients Enrolled NSCLC (n  16)
Sex (male/female) 7/9
Median age (yr) 64 (48–73)
KPS (80/80) 1 vs. 15
Prior regimens 2 (0–3)
Smoking history







KPS, Karnofsky performance status; NSCLC, non-small cell lung cancer; NOS, not
otherwise specified.
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150 mg daily dose, 800 mg weekly, and 1000 mg weekly
dose cohorts, respectively (Table 7). The corresponding val-
ues for erlotinib metabolite, OSI-420, were BLQ (BLQ–
1.58), 4.89 (4.89–10.2), and 80.2 (18.2–117) ng/ml. Al-
though erlotinib 150 mg daily or 800 mg weekly resulted in
negligible erlotinib exposure at the time of subsequent pem-
etrexed dose administration, 1000 mg/wk dose seems to
retain significant erlotinib plasma concentrations at the end of
the cycle.
Recommended Phase II Dose
Based on the findings in this phase I study, the recom-
mended phase II dose in arm A is pemetrexed 500 mg/m2 on
day 1 and erlotinib 1400 mg on days 2, 9, and 16 every 3
TABLE 4. Treatment-related Nonhematologic Adverse Events—All Grade 3/4 and Grade 1/2 Occurring in 1 Patient
Adverse Events
Arm A Arm B
Grade 1 Grade 2 Grade 3 Grade 4 All Grade 1 Grade 2 Grade 3 Grade 4 All
Rash 6 6 — — 12 (55%) 6 8 4 — 18 (90%)
Fatigue 6 3 — — 9 (41%) 9 5 3 — 17 (85%)
Diarrhea 5 3 1 — 9 (41%) 10 2 — — 12 (60%)
AST 5 — — — 5 (23%) 9 1 1 — 11 (55%)
Nausea 6 2 — — 8 (36%) 8 2 — — 10 (50%)
ALT 2 1 — — 3 (14%) 5 3 1 — 9 (45%)
Dry skin 2 1 — — 3 (14%) 6 1 — — 7 (35%)
Anorexia 2 2 — — 4 (18%) 2 3 1 — 6 (30%)
Vomiting 2 2 — — 4 (18%) 5 — 1 — 6 (30%)
Constipation 4 1 — — 5 (23%) 5 — — — 5 (25%)
Hypoalbuminemia — 1 — — 1 (5%) 3 2 — — 5 (25%)
Pruritis — 1 — — 1 (5%) 2 3 — — 5 (25%)
Creatinine 2 1 — — 3 (14%) 3 1 — — 4 (20%)
Alkaline phosphatase 2 — — — 2 (9%) 2 2 — — 4 (20%)
Mucositis 7 — — — 7 (32%) 3 — — — 3 (15%)
Fever 2 — — — 2 (9%) 2 1 — — 3 (15%)
Heartburn 1 — — — 1 (5%) 1 2 — — 3 (15%)
Bilirubin 2 1 — — 3 (14%) — 1 1 — 2 (10%)
Hypokalemia 1 — — — 1 (5%) 2 — — — 2 (10%)
Ocular/visual changes 1 — — — 1 (5%) 1 — 1 — 2 (10%)
Taste alteration 1 — — — 1 (5%) 2 — — — 2 (10%)
Hyponatremia — — — — — 2 — — — 2 (10%)
Alopecia 2 — — — 2 (9%) 1 — — — 1 (5%)
Weight loss 2 — — — 2 (9%) 1 — — — 1 (5%)
Confusion — — — — — — — — 1 1 (5%)
Hyperkalemia — — — — — — — — 1 1 (5%)
Hypermagnesemia — — — — — — — 1 — 1 (5%)
Infection with neutropenia — — — — — — — 1 — 1 (5%)
Hyperpigmentation 2 — — — 2 (9%) — — — — —
Infection without neutropenia — 2 — — 2 (9%) — — — — —
INR — — 2 — 2 (9%) — — — — —
Vaginitis — 2 — — 2 (9%) — — — — —
AST, aspartate transaminase; ALT, alanine aminotransferase; INR, international normalized ratio.
TABLE 5. Treatment-Related Hematologic Adverse Events
Adverse Events
Arm A Arm B
Grade 1 Grade 2 Grade 3 Grade 4 All Grade 1 Grade 2 Grade 3 Grade 4 All
Hemoglobin 8 4 — — 12 (55%) 5 8 3 — 16 (80%)
Leucopenia 3 9 4 — 16 (72%) 4 5 7 1 17 (85%)
Lymphopenia 1 7 3 — 11 (50%) — 4 7 1 12 (60%)
Neutropenia 2 3 6 1 12 (55%) 1 3 6 4 14 (70%)
Neutropenic fever — — 1 — 1 (5%) — — — — —
Platelets 1 1 2 — 4 (18%) 8 2 1 — 11 (55%)
Davies et al. Journal of Thoracic Oncology • Volume 4, Number 7, July 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer866
weeks. Because planned dose escalation was completed with-
out an MTD being identified, it is possible that the weekly
dose of erlotinib could be increased further, although it is
unclear whether this would offer improved efficacy. In arm B,
the recommended phase II dose is pemetrexed 500 mg/m2 on
day 1 and erlotinib 250 mg on days 2 to 16 every 21 days.
DISCUSSION
This phase I study was conducted to determine the
safety and feasibility of combining pemetrexed and two
different intermittent schedules of erlotinib. The intermittent
dosing of erlotinib was designed to facilitate pharmacody-
namic separation of chemotherapy and erlotinib to overcome
hypothesized antagonism. Both schedules were well tolerated
although there was more grade 3 nonhematologic toxicity in
arm B. Although this study involved two agents with known
single-agent efficacy, significant efficacy was seen in both
arms of the study in advanced NSCLC. Although at initial
glance it may seem that the efficacy in arm A is superior,
caution is required in interpreting these results in a nonran-
domized study with multiple dose levels and a variety of solid
tumors. These results suggest that pharmacodynamic separa-
tion of EGFR-TKI and chemotherapy is achievable, although
higher weekly doses of erlotinib may still retain significant
levels at the time of redosing of pemetrexed.
A recent phase II trial has also evaluated intermittent
dosing of erlotinib and chemotherapy (carboplatin with pac-
litaxel).17 High-dose pulse erlotinib given prechemotherapy
in this study resulted in the highest response rate compared
with other doses and schedules. They hypothesize that ad-
ministration of erlotinib at higher doses may increase inhibi-
tion of wild-type EGFR resulting in greater cell death and
may also result in inhibition of off-target kinases. Our study
and that of Riely et al. suggest that for synergistic effects of
erlotinib and chemotherapy to be appreciated, schedule sep-
aration (or intermittent dosing) may be required to maximize
their antitumor effects. In addition, dose of erlotinib may also
play a role in maximizing EGFR-TKI efficacy.
Trials involving the addition of a targeted therapy to
standard cytotoxic chemotherapy frequently involve concur-
rent delivery maintaining the original administration schedule
for each drug. In the majority of NSCLC trials, this strategy
has failed; the combination of EGFR-TKIs, matrix metallo-
proteinase inhibitors, protein kinase C alpha antisense oligo-
nucleotide, and retinoic acid receptor agonists with frontline
platinum-based chemotherapy has demonstrated no benefit
over chemotherapy alone.5–8,18–21 The exceptions are the
monoclonal antibody combinations; bevacizumab (a vascular
endothelial growth factor inhibitor) and cetuximab (an EGFR
inhibitor) combined with chemotherapy have demonstrated a
survival benefit when compared with chemotherapy alone in
NSCLC.22,23 The modest efficacy of cetuximab in combi-
nation with frontline platinum-based chemotherapy in ad-
vanced NSCLC may be due to not only EGFR targeting but
also the antibody-mediated immune mechanisms, antigen-
dependent cell-mediated cytotoxicity, and complement-
dependent cytotoxicity.24
The combination of erlotinib and pemetrexed is of
particular interest in NSCLC as both agents have proven
survival benefit in the second-line setting and an increased
understanding of how to combine these agents in selected
patients may offer improved outcomes. In the NSCLC pop-
ulation, it has been observed that adenocarcinomas are par-
ticularly responsive to EGFR-TKI therapy25 and may be more
likely to benefit from pemetrexed.15,26,27 Preclinical work has
shown that resistance to pemetrexed is associated with up-
regulation of thymidylate synthase in cell lines.28 Higher
thymidylate synthase mRNA and protein expression levels
have been observed in squamous cell carcinomas compared
with adenocarcinoma providing a rationale for the efficacy of
pemetrexed in the latter histology.29,30 Clinical studies sup-
port the use of pemetrexed in nonsquamous versus squamous
histologies. However, when this phase I trial was designed,
the efficacy data in histologic subtypes were not appreciated
and therefore eligibility criteria were not restricted based on
pathology.
TABLE 6. Summary of Response
Response Arm A (n  22) Tumor type (Duration in mo) Arm B (n  20) Tumor Type (Duration in mo)
Partial response 5 All NSCLC (3, 5, 6, 13, 16) 1 Breast (4)
Stable disease 5 Two parotid, one each NSCLC, pancreatic,
prostate (5, 16, 12, 2, 2)
10 Four ovarian, two prostate, two NSCLC,
one each head and neck, and sarcoma
(median 5, range, 2–8)
Progressive disease 8 5
NSCLC, non-small cell lung cancer.
TABLE 7. Trough Plasma Concentrations
150 mg/d (d 2–16) 800 mg/wk (d 2, 9, 16) 1000 mg/wk (d 2, 9, 16)
Erlotinib concentration (ng/ml) median (range) 5.06 (BLQ–12.2) 96.7 (82.4–173) 807 (168–884)
OSI-420 concentration (ng/ml) median (range) BLQ (BLQ–1.58) 4.89 (4.89–10.2) 80.2 (18.2–117)
Pyruvate kinase samples taken on day 1, cycle 2 before dosing.
BLQ, below level of quantification.
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The study reported herein used a novel schedule of
erlotinib in combination with chemotherapy (pemetrexed).
Based on the tolerability and preliminary efficacy of this
combination in NSCLC, a randomized phase II study of
pemetrexed with or without erlotinib on an intermittent
schedule (days 2–16) is ongoing. This dosing schedule was
selected, based on the promising efficacy seen in this trial and
in the phase II trial with docetaxel and intermittent erlotinib
(days 2–16) conducted by our group.31 Further studies of
intermittent erlotinib with other chemotherapeutics in ad-
vanced NSCLC are warranted.
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